UCLA BIOMEDICAL is a generic drug manufacturer focused on Oncology, Neurology.
UCLA BIOMEDICAL's Key Drugs
UCLA BIOMEDICAL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
UCLA BIOMEDICAL's Recent FDA Approvals
New NDA/BLA approvals for UCLA BIOMEDICAL over the last two years — novel drugs only, excluding generics and label supplements.
UCLA BIOMEDICAL's Therapeutic Areas
UCLA BIOMEDICAL's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
UCLA BIOMEDICAL's Top Competitors
UCLA BIOMEDICAL's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
UCLA BIOMEDICAL Pipeline Snapshot
Active clinical trials for UCLA BIOMEDICAL across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2013-06-27
- Latest
- 2013-06-27
- Applications
- 2